clinical trial · NCT04171700
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
Solid TumorRucaparib
brief summary
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
started
Jan 16, 2020
primary completion
Jun 8, 2022
completion
Jul 15, 2022
last updated
Oct 2, 2023
official title
A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol